Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,143,277

« Back to Dashboard

Summary for Patent: 6,143,277

Title: Metered dose inhaler for salmeterol
Abstract:A metered dose inhaler having part or all of its internal metallic surfaces coated with one or more fluorocarbon polymers, in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising salmeterol, or a salt thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents and one or more excipients.
Inventor(s): Ashurst; Ian C. (Ware, GB), Herman; Craig S. (Raleigh, NC), Li; Li (Scotch Plains, NJ), Riebe; Michael T. (Raleigh, NC)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC) Glaxo Group Limited (Greenford, GB)
Application Number:08/770,533
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery; Device; Use; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 131st percentile
Forward Citations: 14th percentile

No matches for this query

Premature patent expiration for: 6,143,277

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
6,143,277 November 07, 2012

International Patent Family for Patent: 6,143,277

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)9701113► subscribe
African Regional IP Organization (ARIPO)979► subscribe
Austria250439► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.